Lisata Therapeutics Inc (LSTA)

[Viperciara]

Caladrius Biosciences Receives $14.57 Average PT from Analysts (NASDAQ:CLBS)
Posted on July 16, 2015 by Stefani Robinson in Consensus Rating Articles, Investing










Caladrius Biosciences logoCaladrius Biosciences (NASDAQ:CLBS) has received a consensus recommendation of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $14.38.

CLBS has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a research note on Tuesday. Analysts at Maxim Group reiterated a “buy” rating on shares of Caladrius Biosciences in a research note on Thursday, June 25th. Analysts at Benchmark Co. lowered their price target on shares of Caladrius Biosciences from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Finally, analysts at MLV & Co. initiated coverage on shares of Caladrius Biosciences in a research note on Monday, April 6th. They set a “buy” rating and a $14.00 price target on the stock.

Shares of Caladrius Biosciences (NASDAQ:CLBS) opened at 1.90 on Monday. Caladrius Biosciences has a 52 week low of $1.80 and a 52 week high of $7.22. The stock has a 50-day moving average of $2.05 and a 200-day moving average of $2.97.

Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market.
http://sleekmoney.com/caladrius-biosciences-receives-14-57-average-pt-from-analysts-nasdaqclbs/351084/